Cubist Pharmaceuticals, Inc. to Pay Up to $1.6 Billion for Two Antibiotics Makers

Published: Jul 31, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cubist Pharmaceuticals Inc has agreed to pay up to $1.6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise. The widely praised deals will give Cubist, one of the few big players in U.S. antibiotics in the United States, an additional $600 million to $1 billion in revenue on an annual basis from the companies' lead drugs. Antibiotics has often been shunned by many big pharma firms as a field of research due to poor returns.

Help employers find you! Check out all the jobs and post your resume.

Back to news